OSR (NASDAQ:OSRH) Announces Earnings Results

OSR (NASDAQ:OSRH) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, Zacks reports. OSR had a negative return on equity of 13.53% and a negative net margin of 619.82%.The firm had revenue of $0.48 million for the quarter.

OSR Price Performance

Shares of OSRH stock traded down $0.00 during midday trading on Thursday, hitting $0.61. The company had a trading volume of 273,015 shares, compared to its average volume of 5,015,016. The stock has a market cap of $21.55 million, a price-to-earnings ratio of -0.48 and a beta of 0.86. The company’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.58. OSR has a 52-week low of $0.38 and a 52-week high of $1.79.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of OSR in a research report on Friday, March 27th. Wall Street Zen upgraded shares of OSR from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Hedge Funds Weigh In On OSR

An institutional investor recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission. 55.30% of the stock is owned by hedge funds and other institutional investors.

OSR Company Profile

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.